Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Tax Provisions (2017 - 2025)

Historic Tax Provisions for Avalo Therapeutics (AVTX) over the last 9 years, with Q3 2025 value amounting to $11000.0.

  • Avalo Therapeutics' Tax Provisions rose 17857.14% to $11000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $149000.0, marking a year-over-year increase of 175555.56%. This contributed to the annual value of $114000.0 for FY2024, which is 71428.57% up from last year.
  • Per Avalo Therapeutics' latest filing, its Tax Provisions stood at $11000.0 for Q3 2025, which was up 17857.14% from $16000.0 recorded in Q2 2025.
  • Avalo Therapeutics' Tax Provisions' 5-year high stood at $114000.0 during Q4 2024, with a 5-year trough of -$200000.0 in Q2 2021.
  • Its 5-year average for Tax Provisions is $684.21, with a median of $8000.0 in 2021.
  • Over the last 5 years, Avalo Therapeutics' Tax Provisions had its largest YoY gain of 136666.67% in 2024, and its largest YoY loss of 27500.0% in 2024.
  • Over the past 5 years, Avalo Therapeutics' Tax Provisions (Quarter) stood at $4000.0 in 2021, then surged by 100.0% to $8000.0 in 2022, then crashed by 212.5% to -$9000.0 in 2023, then soared by 1366.67% to $114000.0 in 2024, then tumbled by 90.35% to $11000.0 in 2025.
  • Its last three reported values are $11000.0 in Q3 2025, $16000.0 for Q2 2025, and $8000.0 during Q1 2025.